-
2023-503219-14-01
10
2024-05-22
systemic sclerosis associated interstitial lung disease
-
2023-505929-14-00
5
2024-05-21
Systemic Lupus Erythematosus
-
2022-501648-14-00
9
2024-05-05
Relapsed or refractory CD19 positive B cell malignancies (adult ALL, a
-
2023-507632-20-00
5
2024-05-01
Multiple Myeloma
-
2022-500305-40-00
9
2024-04-10
Chronic Lymphocytic Leukemia
-
2022-502751-61-00
4
2024-04-10
Advanced stage III, IVA, IVB laryngeal or II, III, IVA, IVB hypopharyn
-
2024-514865-20-00
4
2024-04-10
Glioblastoma
-
2022-502405-15-01
4
2024-04-08
Mantle Cell Lymphoma (MCL)
-
2024-515267-59-00
4
2024-04-07
Acute myeloid leukemia
-
2023-503208-94-00
6
2024-04-04
Prostate cancer
-
2023-508502-18-00
5
2024-03-19
Alport syndrome
-
2023-505267-36-00
5
2024-03-15
Glioblastoma
-
2022-501453-36-00
5
2024-02-23
Breast cancer
-
2023-504146-60-00
10
2024-02-07
lymphatic malformations associated with PIK3CA mutation
-
2023-503938-52-00
4
2024-01-26
Progressive Glioblastoma
-
2023-504322-19-00
5
2024-01-10
Patients in the intensive care unit on ventilation with pneumonia and
-
2023-503582-35-00
6
2023-10-26
Staphylococcus aureus bacteremia
-
2023-503558-10-00
5
2023-10-13
oligometastatic pancreatic cancer
-
2022-502157-33-00
7
2023-09-18
B-Cell Malignancies
-
2022-502732-39-00
10
2023-09-01
Previously treated non-ocular advanced melanoma
-
2024-512320-11-00
5
2023-08-09
Primary diffuse large B-cell lymphoma of the central nervous system
(P
-
2022-501822-39-00
9
2023-07-31
Glioblastoma
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2022-501999-26-00
5
2023-07-12
Severe Hypertriglyceridemia (SHTG)